Finance

Gene therapy company reports loss of $0.34 per share

Published in Drug Week, June 11th, 2004

Chromos Molecular Systems, Inc., (CHR) announced its financial results for the fiscal year ended December 31, 2003.

"In 2003 we received the strongest validation to date for our proprietary ACE System technology, as we signed our first commercial manufacturing deal in cellular protein production," said Alistair Duncan, president and CEO of Chromos. "This deal with Cambridge Antibody Technology was a milestone achievement that demonstrates the market's growing acceptance of our technology and proves its commercial viability. As the market potential of the ACE System's use in cellular protein production is realized, anticipated revenues from out-licensing deals will...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-06-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry